Filtered By:
Management: Food and Drug Administration (FDA)
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 1725 results found since Jan 2013.
Structural-Based Virtual Screening of FDA-Approved Drugs Repository for NSP16 Inhibitors, Essential for SARS-COV-2 Invasion Into Host Cells: Elucidation From MM/PBSA Calculation
Bioinform Biol Insights. 2023 Jul 31;17:11779322231171777. doi: 10.1177/11779322231171777. eCollection 2023.ABSTRACTNSP16 is one of the structural proteins of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) necessary for its entrance to the host cells. It exhibits 2'O-methyl-transferase (2'O-MTase) activity of NSP16 using methyl group from S-adenosyl methionine (SAM) by methylating the 5-end of virally encoded mRNAs and shields viral RNA, and also controls its replication as well as infection. In the present study, we used in silico approaches of drug repurposing to target and inhibit the SAM binding site ...
Source: Bioinformatics and Biology Insights - August 3, 2023 Category: Bioinformatics Authors: Subodh Kumar Harvinder Singh Manisha Prajapat Phulen Sarma Anusuya Bhattacharyya Hardeep Kaur Gurjeet Kaur Nishant Shekhar Karanveer Kaushal Kalpna Kumari Seema Bansal Saniya Mahendiratta Arushi Chauhan Ashutosh Singh Rahul Soloman Singh Saurabh Sharma Pr Source Type: research
With new flurry of clinical trials, NIH finally seeks treatments for Long Covid
The National Institutes of Health (NIH) yesterday announced
new clinical trials to test a diverse array of treatment strategies
—from an intravenous immune drug to light therapy and a dietary supplement—in people with Long Covid, the disabling syndrome that can follow infection with the pandemic coronavirus. The focus is on mitigating some of the most common and debilitating symptoms including brain fog and sleep troubles.
Most of the trials will include 100 to 300 people with Long Covid and will start to enroll this year, officials said. One, a multiweek study of the antiviral Paxlovid, has started to sign ...
Source: ScienceNOW - August 1, 2023 Category: Science Source Type: news
Gaining perspective on messenger RNA coronavirus disease 2019 vaccination risk
Discussing COVID-19 vaccinations will be ongoing ad infinitum. “Vaccine makers should target the XBB variant of the coronavirus in a shot to be available in the fall,” according to an advisory panel to the Food and Drug Administration. Although the COVID-19 landscape has improved this year, “those who remain vulnerable include the unvaccinated; people who are immunocompromised; and those who have diabetes or chronic kidney, lung, cardiovascular or neurologic diseases. People 65 and older are also at risk and that rises with age.”1
Source: Journal of the American Academy of Dermatology - June 27, 2023 Category: Dermatology Authors: Warren R. Heymann Tags: A clinician's perspective Source Type: research
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
Haematologica. 2023 Jun 22. doi: 10.3324/haematol.2023.283015. Online ahead of print.ABSTRACTAZD7442 (tixagevimab-cilgavimab) is a combination of two human monoclonal antibodies for preexposure prophylaxis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among highrisk patients who do not mount a reliable vaccine response. Foremost among these are hematologic malignancy patients with limited clinical trial or real-world experience to assess the effectiveness of this combination treatment since the emergence of Omicron and its subvariants. We performed a retrospective study of 892 highrisk hematolog...
Source: Haematologica - June 22, 2023 Category: Hematology Authors: Justin C Laracy Judy Yan Samantha N Steiger Carrie A Tan Nina Cohen Elizabeth V Robilotti Jerome Fender Sara Cohen Neha Korde Melissa Lee-Teh Ariela Noy Joseph H Oved Lindsey E Roeker Gunjan Shah N Esther Babady Mini Kamboj Susan K Seo Source Type: research
